Kuric

Quick links to important sections

Kuric

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kuric

Understanding Kuric

Kuric is a topical antifungal medication formulated to address various fungal infections of the skin. It belongs to a class of medications known as azole antifungals, which are designed to interfere with the growth and reproduction of fungal cells.

Primary Function

The active component in Kuric works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes. By disrupting the integrity of these membranes, the medication helps to stop the spread of the infection and allows the skin to heal. It is specifically used for conditions caused by dermatophytes or yeasts.

Common Applications

Kuric is typically utilized in the management of several common skin conditions, including:

  • Tinea Pedis: Commonly known as athlete's foot, which affects the skin on the feet and between the toes.
  • Tinea Corporis: Also known as ringworm, characterized by circular, red, itchy patches on the body.
  • Tinea Cruris: Often referred to as jock itch, which affects the groin and inner thigh areas.
  • Seborrheic Dermatitis: A condition that causes scaly patches, red skin, and stubborn dandruff, often on the scalp or oily areas of the body.
  • Tinea Versicolor: A fungal infection that causes small, discolored patches of skin.

Composition and Delivery

This medication is primarily available in cream or foam formulations, which are designed for direct application to the affected areas of the skin. These vehicles are chosen to ensure the active ingredient remains in contact with the site of infection for the necessary duration to be effective.

Regulatory References

  1. Topical Ketoconazole Use (EMA)

What side effects are possible with Kuric?

The safety profile of Kuric, a topical ketoconazole product, is defined by regulatory documents, primarily featuring localized reactions at the application site. Adverse events are grouped by frequency and the physiological system affected, providing a structured summary of potential risks.

Classification Examples of Officially Documented Adverse Reactions (SOC Group)
Common Burning sensation at application site, erythema (redness), pruritus (itching) (Skin and Subcutaneous Tissue Disorders)
Uncommon Hypersensitivity, blistering, contact dermatitis, rash, dry skin, skin irritation (Immune System Disorders, Skin Disorders)
Not Known Urticaria, angioedema, hair discoloration, oily/dry hair, exfoliative rash, eye irritation (Multiple Systems)

Serious adverse reactions documented in official labeling include severe hypersensitivity reactions (such as anaphylaxis) and angioedema. The product is contraindicated in individuals with a known hypersensitivity to ketoconazole or any non-active component in the formulation. Furthermore, regulatory guidelines explicitly require that contact with the eyes be avoided.

Safety notes tied to exposure indicate that localized reactions like burning and itching are often observed early in the course of treatment.

For specific populations, the minimal systemic absorption of the topical formulation results in fewer specific warnings. The official label notes that for pregnancy and lactation, use is generally considered only if the potential benefits are judged to outweigh the possible risks. Safety and effectiveness have not been fully established in all pediatric patient populations.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Kuric (topical ketoconazole) establishes that systemic overdose is considered unlikely from routine or excessive topical application, as detectable systemic absorption is not expected with this formulation.

Overdose Scope (Official Regulatory Information) Documented Findings / Mandated Actions
Documented Overdose Manifestations Local skin reactions including erythema (redness), oedema (swelling), and a burning sensation may occur from excessive topical application. These effects typically resolve upon discontinuation of treatment.
Exposure-Related Factors Accidental oral ingestion of the topical product is the primary scenario addressed by the emergency protocol. Severe outcomes associated with the oral tablet form, such as hepatotoxicity or adrenal insufficiency, are not documented for the topical overdose profile.
Emergency-Response Statements When accidental oral ingestion occurs, the official guidance mandates immediate contact with a health care provider or a Poison Control Center. Management involves the institution of symptomatic and supportive measures, as no specific antidote is documented.

Connection to the overall overdose profile: Regulatory guidance clearly differentiates the management of local effects, which simply require discontinuing the product, from the immediate requirement to seek professional help following accidental swallowing. This profile confirms that urgent attention is required solely for ingestion.

Therapeutic Uses of Kuric

What Kuric Treats: Main Uses and Benefits

Kuric (topical ketoconazole) is used in situations involving certain distressing symptoms that are driven by the overgrowth of fungi or yeasts. This medicine is applied across domains where additional symptomatic support is needed for addressing conditions where functional stability becomes affected, offering assistance in managing these common dermatological issues.

The conditions for which Kuric is relevant include Tinea corporis (ringworm of the body), Tinea cruris (jock itch), Tinea pedis (athlete's foot), as well as Pityriasis Versicolor, Cutaneous Candidiasis, and Seborrheic Dermatitis.

This topical agent helps address symptom clusters that may become intense or disruptive, such as persistent itching, redness, flaking, and scaling. It contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability by addressing the visible manifestations.

“It provides support that helps ease the overall symptom burden associated with recurrent fungal and yeast-driven skin conditions.”


Quick Fact: Managing Persistent Itching (Kuric is relevant for managing symptoms that interfere with daily comfort, particularly the challenging pruritus and irritation associated with many fungal rashes.)

Regulatory References

  1. DailyMed (NIH/NLM)

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Kuric — Official Regulatory Information

Regulatory agencies define the eligibility for Kuric (ketoconazole topical) based on a few key factors, primarily focusing on allergies, age, and reproductive status.


Contraindications (Must NOT Use)

  • Hypersensitivity: Use is strictly forbidden for individuals with a known allergy to ketoconazole or any of the product's inactive ingredients (excipients), which may include sulfites in some formulations.

Age-Related Eligibility

  • Children: Safety and effectiveness are not established for the cream and some shampoo formulations in children younger than 12 years of age. Use in this group is generally restricted by the regulatory label. Older adults are generally eligible, though increased sensitivity to side effects may be a consideration.

Conditional or Restricted Use

  • Pregnancy and Lactation: Use during pregnancy (e.g., FDA Pregnancy Category C) or while breastfeeding is conditional. The regulatory guidance states the medicine should only be used if the potential benefit justifies the potential risk to the fetus or nursing infant, due to limited data on systemic absorption.
  • Administration Site: The product is for external use only and must not be used in the eyes, mouth, nose, or intravaginally.

Official Eligibility Structure

The regulatory documentation creates a clear structure: Hypersensitivity establishes an absolute contraindication, while Pediatric Use is restricted due to a lack of established safety and efficacy data. Reproductive Status requires a mandatory clinical risk-benefit assessment, limiting use to cases of justified need.

What should I know about interactions with other medicines?

Kuric Interactions with other medicines and products

The interaction profile for Kuric (topical ketoconazole) differs significantly from the systemic oral form due to its minimal systemic absorption following application. Regulatory documents state that clinically relevant systemic drug-drug interactions are not expected in non-pregnant adults because plasma concentrations are often undetectable.


Documented Interaction Patterns

Category Regulatory Status for Topical Kuric
Systemic Contraindications None explicitly listed based on drug-drug interactions.
Pharmacokinetic Interactions Not expected; formal studies are typically not performed due to negligible absorption.
Food/Alcohol Interactions None documented as relevant or requiring restriction.

Procedural and Population-Specific Notes

The only specific interaction management protocol relates to Topical Corticosteroids. When transitioning from long-term use of potent topical corticosteroids, a gradual withdrawal protocol is required to avoid a localized rebound effect upon abrupt discontinuation.

A population-specific note exists for infants. Regulatory data indicates that detectable systemic plasma levels of ketoconazole may occur in infants with extensive use (high volume applied to a large body surface area). This finding suggests a potential for systemic interaction risk under specific conditions in that group, which is otherwise absent in adults.

Mechanism of Action

Kuric's mechanism is defined by the precise targeting of essential biological processes within the fungal organism itself. Its action is focused on disrupting the pathogen's structure and viability, which leads to the predictable suppression of the fungal burden.


Molecular Blockade of Fungal Sterol Synthesis

The mechanism of Ketoconazole is defined by the selective inhibition of a key fungal enzyme, Cytochrome P450 14alpha-demethylase (CYP51A1). This enzyme is crucial for the conversion of sterol precursors into ergosterol, the fundamental component of the fungal cell membrane. The drug's targeted action halts this vital synthesis process through a non-competitive binding interaction, initiating the primary cellular disruption.


Pathogen Structural and Functional Compromise

The consequence of enzyme blockade is a dual physiological effect on the pathogen: the depletion of ergosterol and the subsequent accumulation of toxic intermediate sterol precursors within the fungal cell. This compromise causes the fungal cell membrane to lose structural integrity and exhibit abnormal fluidity, thereby preventing the cell from maintaining homeostasis and normal function. This mechanism results in the cessation of replication and functional elimination of the fungal biological presence.


Constraints on Mechanistic Efficacy

The effectiveness of this mechanism is constrained by fungal countermeasures. These constraints include the pathogen's ability to develop mutations in the CYP51A1 enzyme that reduce the drug's binding affinity, or the upregulation of efflux pumps that actively transport the drug out of the cell. These mechanisms limit the concentration of Ketoconazole that reaches the target, thereby directly impacting the intensity of the cellular compromise.

Dosage and Administration Information

How Kuric is Used: Official Administration and Dosing

Kuric (topical ketoconazole) is indicated for external topical use on the skin or scalp and is not to be used orally, ophthalmically, or intravaginally. The medicine is available in various forms, including Cream (2%), Shampoo (1% or 2%), Gel (2%), and Foam (2%), with specific instructions governing the proper frequency and duration for each treated condition.


Standard Labeled Dosing and Duration

The standard adult dosing schedule and duration are dependent on the targeted fungal infection as defined in standard prescribing information.

Condition (Indication) Dosage Form Frequency Standard Duration
Tinea Corporis, Cruris, Versicolor 2% Cream Once daily 2 weeks
Tinea Pedis (Athlete's Foot) 2% Cream Once daily 6 weeks
Seborrheic Dermatitis 2% Cream or Foam Twice daily 4 weeks
Seborrheic Dermatitis 2% Gel Once daily 2 weeks

Key Administration Instructions

Specific application techniques and constraints must be followed for effective use:

  • 2% Shampoo: When treating Pityriasis Versicolor, the shampoo must be applied to the damp skin, lathered, and explicitly left in place for 5 minutes before rinsing.
  • 2% Gel: The treated area must not be washed for at least 3 hours after application.
  • 2% Foam/Gel: These products are flammable, and patients must avoid fire, flame, and smoking during and immediately following application.

Population Rules

Adult dosing regimens are established for patients 12 years of age and older. Safety and effectiveness have not been established for children under 12 years of age; any use in this population must be under medical supervision.

Recent Clinical Evidence

Research evidence / Overview of Studies for Kuric

This overview summarizes the official scientific research that has examined the component in Kuric (topical ketoconazole), focusing only on the types of studies conducted, the outcomes research examined, and the known limitations and uncertainties within the evidence base. This information research describes the evidence landscape and is not clinical advice.


Evidence for Tinea Corporis, Tinea Cruris, and Tinea Pedis (Ringworm and Athlete's Foot)

The evidence was evaluated in short-term Randomized Controlled Trials (RCTs) and controlled clinical studies for outcomes related to fungal presence in ringworm, jock itch, and athlete’s foot. These trials research examined patient populations, including Adults and Adolescents, with a confirmed fungal infection.

The specific endpoints studies explored included measurements of mycological clearance (laboratory confirmation of fungal outcomes) and assessments of clinical resolution (investigator’s assessment of the visible state of skin signs). Trial reports findings describe patterns observed in the studies in measurements related to fungal outcomes and patient-reported outcomes describing perceived discomfort. The aggregated evidence contributes to the broader evidence landscape for the drug class.


Evidence for Seborrheic Dermatitis

The use of topical ketoconazole for Seborrheic Dermatitis has been evaluated in an extensive number of Randomized Controlled Trials (RCTs), as well as Systematic Reviews. These studies research examined the topical application for managing this chronic condition, which is characterized by fluctuating or episodic manifestations involving the scalp, face, and trunk.

Long-term effects are not fully established for this chronic condition. A significant limitation research highlights is the chronic, recurrent nature of Seborrheic Dermatitis, meaning there is limited information for long-term outcomes regarding the optimal approach to maintenance therapy after initial symptom management.


What the Research Indicates is Still Uncertain

Official and peer-reviewed scientific literature highlights several areas where research is ongoing and certainty remains low:

  • Long-Term Durability: There is limited information for long-term outcomes demonstrating sustained remission or freedom from recurrence.
  • Subgroup Findings: Data for certain groups remain insufficient, including evidence for very young children or patients with complex health issues.
  • Comparative Effectiveness: Comparative evidence is lacking for some indications when assessing the outcomes of this specific formulation against every newer topical antifungal agent now available on the market.
  • Study Consistency: For some uses, evidence quality varies across studies, and the sample sizes were modest in some older reports.

Key Studies & References

  1. Ketoconazole Topical Cream - Official Prescribing Information (DailyMed/NIH)
  2. Ketoconazole 2% Shampoo - Official Prescribing Information (DailyMed/NIH)
  3. Topical ketoconazole for seborrhoeic dermatitis (Cochrane Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Kuric (FAQ)

Q: Is Kuric safe to take long-term?

A: Regulatory research highlights that long-term effects for this topical medicine are not fully established, particularly for chronic conditions like Seborrheic Dermatitis. Official studies indicate limited information concerning sustained remission or the long-term durability of outcomes beyond the initial treatment periods.

Q: What are the most commonly reported side effects of Kuric?

A: According to official documentation, the most commonly reported reactions occur at the application site. These include a burning sensation, redness (erythema), and itching (pruritus). These local skin reactions are generally expected and defined in regulatory safety information.

Q: What does the FDA label say about Kuric's potential for dependence?

A: Official classification documents from regulatory bodies indicate that this medicine is not designated as a controlled substance. The topical formulation does not carry a risk for abuse or dependence.

Q: Does Kuric cause weight gain or loss?

A: Weight changes (gain or loss) are not listed among the commonly or uncommonly documented adverse reactions for the topical formulation. This is consistent with the medicine's minimal systemic absorption into the bloodstream.

Q: Can Kuric make you feel tired or drowsy?

A: Tiredness or drowsiness are not listed as commonly reported side effects in the product's official safety documents. Systemic effects are generally not expected with the topical product due to minimal absorption.

Q: How quickly does Kuric typically start working?

A: Official information from the NIH indicates that for the cream, improvements are generally expected at the beginning of treatment, but the full course must be completed. For the shampoo used for Seborrheic Dermatitis, initial signs of improvement may be seen within the first two to four weeks.

Q: Is it normal to have mild headaches after starting Kuric?

A: Headaches are not listed among the common or uncommon side effects documented for this topical product. However, official post-marketing reports have occasionally included headache as a reported symptom, typically without defined frequency.

Q: Does Kuric interact with common over-the-counter pain relievers?

A: Due to the minimal amount of the medicine absorbed into the body, clinically relevant systemic drug-drug interactions with other medicines, including over-the-counter pain relievers, are generally not expected.

Q: Is there a list of medicines or supplements to avoid while taking Kuric?

A: The official documentation does not list specific medicines or supplements to avoid when using Kuric. This is because clinically relevant systemic drug-drug interactions are not expected due to the product's minimal absorption.

Q: What if I experience a potential side effect from Kuric?

A: Patients are advised by health authorities to consult a healthcare provider if they experience any concerning reactions or side effects while using the medicine. This guidance helps ensure appropriate monitoring and management.

Q: Does Kuric interact with birth control pills?

A: Based on the pharmacological profile, clinically relevant systemic interactions are not expected with the topical product due to minimal absorption. However, specific documentation for all oral contraceptives is limited.

Q: What should I expect in the first few days of taking Kuric?

A: Safety notes tied to exposure indicate that localized reactions at the site of application, such as a burning sensation and itching, are often observed early in the course of treatment. This is a common pattern defined in the product information.

Q: Will stopping Kuric suddenly cause any issues?

A: Regulatory guidance advises a gradual withdrawal protocol only when transitioning from long-term use of potent topical corticosteroids to Kuric, in order to avoid a localized rebound effect. There is no comparable warning for stopping Kuric alone.

Q: Does alcohol consumption affect how Kuric works?

A: Regulatory documents state that no food or alcohol interactions are documented as relevant or requiring restriction with the topical formulation. This is due to the minimal systemic presence of the medicine in the body.

Q: Is Kuric okay to take with caffeine?

A: Regulatory documents state that no food or beverage interactions are documented as relevant or requiring restriction with the topical formulation. This is consistent with the minimal systemic absorption of the product.

Q: Do studies show Kuric is effective for all types of its target condition?

A: Official research highlights that the evidence quality varies across studies, and data for certain patient subgroups, such as very young children or those with complex health issues, remain insufficient. Therefore, its effectiveness is not definitively established for all possible patient types or complex manifestations.

Q: What kind of research has been done on the long-term effects of Kuric?

A: Official research has evaluated the topical formulation in numerous short-term, controlled trials (RCTs) for initial clearance and symptom management. However, studies on the long-term durability of outcomes, meaning sustained remission or freedom from recurrence, are limited.

Q: Can Kuric affect my ability to drive or operate machinery?

A: Based on the product's minimal systemic absorption, the topical formulation is not generally expected to impair the ability to drive or operate machinery. Systemic side effects that could affect these abilities are generally not expected for the topical form.

Q: What does official information say about Kuric and mental health side effects?

A: Mental health-related side effects, such as confusion or anxiety, are not listed among the documented adverse reactions for the topical formulation. This is consistent with its minimal systemic absorption into the body.

Q: Is Kuric known to interact with herbal supplements like St. John's Wort?

A: The official documentation does not list specific herbal supplements, such as St. John's Wort, to avoid. Clinically relevant systemic drug-drug interactions with supplements are generally not expected due to the topical product's minimal absorption.

Q: Are there any specific foods I should avoid while on Kuric?

A: Regulatory documents state that no food or alcohol interactions are documented as relevant or requiring restriction with the topical formulation.

Q: How long does Kuric stay in your system after you stop taking it?

A: Due to the topical nature of the medicine, only minimal amounts are absorbed into the bloodstream. These small amounts of medicine are typically cleared rapidly from the body once treatment is stopped.

Q: Can Kuric affect blood pressure?

A: The topical formulation is not expected to affect blood pressure. The amount of medicine absorbed into the bloodstream is minimal, making a systemic effect on blood pressure generally not expected.

Q: Is Kuric only available by prescription?

A: Kuric, which contains ketoconazole, is available in both prescription-only forms and lower-strength formulations that are sold over the counter (OTC).

Q: Can Kuric be taken with common vitamins?

A: The official documentation does not list specific vitamins or supplements that would cause clinically relevant systemic drug-drug interactions. This is due to the product's minimal absorption into the bloodstream.

How should Kuric be stored and disposed of?

How to Store and Dispose of Kuric?

Kuric (topical ketoconazole) must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F and 77 F). It must be kept in the original, tightly closed container and protected from freezing, excessive heat, moisture, and light. Store the medicine out of the reach of children and pets.

For disposal, utilize a community drug take-back program as the preferred method. If unavailable, unused medicine should be mixed with an undesirable substance, sealed in a bag, and placed in household trash. Do not flush Kuric down the toilet. The pressurized foam container must not be punctured or incinerated.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Kuric found in:

A-Z Index: